rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2024-3098GMFOKMrpcardio-3098Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИRussian extreme hypertriglyceridemia registy (REGGI): a call to actionРоссийский регистр экстремальной гипертриглицеридемии (РЭГГИ): призыв к действиюhttps://orcid.org/0000-0003-2760-2792ЧубыкинаУ. В.ChubykinaU. V.

Чубыкина Ульяна Валериевна 

 Москва 

Uliana V. Chubykina

Moscow 

uliankachubykina@gmail.comhttps://orcid.org/0000-0002-1518-6552ЕжовМ. В.EzhovM. V.

Ежов Марат Владиславович  

 Москва 

Marat V. Ezhov 

Moscow 

marat_ezhov@mail.ruhttps://orcid.org/0000-0001-7004-0903СоколовА. А.SokolovA. A.

Соколов Алексей Альбертович 

 Москва 

Aleksey A. Sokolov 

Moscow 

dr.sokolov@list.ruhttps://orcid.org/0000-0002-8249-343XВасильевП. А.VasiluevP. A.

Васильев Петр Андреевич  

Москва 

Peter А. Vasiluev 

Moscow 

Vasiluev1993@yandex.ruhttps://orcid.org/0000-0002-8366-2004ИвановаО. Н.IvanovaO. N.

Иванова Ольга Николаевна 

 Москва 

Olga N. Ivanova 

Moscow 

ion10@bk.ruhttps://orcid.org/0000-0002-5020-1180ЗахароваЕ. Ю.ZakharovaE. Y.

Захарова Екатерина Юрьевна 

Москва 

Ekaterina Y. Zakharova 

 Moscow 

doctor.zakharova@gmail.comФГБУ «НМИЦ Кардиологии имени академика Е.И. Чазова» Минздрава РоссииРоссияE. I. Chazov National Medical Research Centre of CardiologyRussian FederationМедико-генетический научный центр им. акад. Н. П. БочковаРоссияN. P. Bochkov Research Centre for Medical GeneticsRussian Federation202402122024205566573Copyright © Chubykina U.V., Ezhov M.V., Sokolov A.A., Vasiluev P.A., Ivanova O.N., Zakharova E.Y., 20242024Чубыкина У.В., Ежов М.В., Соколов А.А., Васильев П.А., Иванова О.Н., Захарова Е.Ю.Chubykina U.V., Ezhov M.V., Sokolov A.A., Vasiluev P.A., Ivanova O.N., Zakharova E.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/3098

Hypertriglyceridemia (HTG) is associated with an increased risk of atherosclerotic cardiovascular disease, pancreatitis developing, and all-cause mortality. The risk escalates with rising triglyceride levels and is most significant in extreme HTG (triglycerides above 10 mmol/L). According to epidemiological studies in the Russian Federation, the extreme HTG prevalence varies between 0.1-0.2% (affecting 146,000 to 292,000 Russians). Extreme HTG can be monogenic or polygenic (multifactorial), this determines the clinical course of the disease. Registries are among the most effective models for studying disease development, as they can compile information on clinical, laboratory, instrumental, and molecular data from patients with specific pathologies, and enable analysis of this data and the subsequent development and integration of improved diagnostic and treatment models into clinical practice. The establishment of a registry for extreme HTG will deepen our understanding of the hyperlipidemia nature, regional characteristics of its prevalence, and the phenotypic manifestation of the disease in our country. It will also facilitate the organized and standardized collection of patient information. Data obtained through registry monitoring will enhance diagnostic and monitoring approaches for patients with extreme HTG in practical healthcare settings. The purpose is to present current information on the diagnosis, monitoring, and treatment of patients with extreme HTG, and to announce the creation of the Russian Extreme hypertriGlyceridemia reGIstry (REGGI).

Гипертриглицеридемия (ГТГ) ассоциирована с увеличением риска развития атеросклеротических сердечно-сосудистых заболеваний, панкреатита и смертности от всех причин. При этом риск возрастает по мере увеличение уровня триглицеридов и наиболее значим при экстремальной ГТГ (концентрация триглицеридов более 10 ммоль/л). По данным эпидемиологических исследований в Российской Федерации, распространенность экстремальной ГТГ варьирует в пределах 0,1-0,2% (от 146 до 292 тысяч россиян). Экстремальная ГТГ может иметь моногенный и полигенный (многофакторный) характер, что определяет клиническое течение заболевания. Регистры являются одной из наиболее оптимальных моделей при изучении течения заболевания, поскольку могут включать информацию о клинических, лабораторно-инструментальных, молекулярных данных пациентов с определенной патологией, и дают возможность проводить анализ этой информации с последующей разработкой и интеграцией в клиническую практику улучшенной модели диагностики и лечения. Создание регистра экстремальной ГТГ способствует углублению знания о природе гиперлипидемии, территориальных особенностях распространения и фенотипического проявления заболевания в нашей стране, позволит организовать качественный и унифицированный сбор информации о пациентах. Полученные в рамках регистрового наблюдения данные способствуют совершенствованию подходов к диагностике и мониторингу больных с экстремальной ГТГ в практическом звене здравоохранения. Цель обзора — освещение актуальной информации по диагностике, наблюдению и лечению пациентов с экстремальной ГТГ и уведомление о создании российского Регистра Экстремальной ГипертриГлИцеридемии (РЭГГИ).

триглицеридырегистрэкстремальная гипертриглицеридемиялипидные центрысердечно-сосудистые заболеванияпанкреатитхиломикронемияполигенная гипертриглицеридемияtriglyceridesregistryextreme hypertriglyceridemialipid centerscardiovascular diseasespancreatitischylomicronemiapolygenic hypertriglyceridemiaReferencesGill PK, Dron JS, Hegele RA. Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol. 2021;36(3):264-71. DOI: 10.1097/HCO.0000000000000839.Gill PK, Dron JS, Hegele RA. Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol. 2021;36(3):264-71. DOI: 10.1097/HCO.0000000000000839.Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806. DOI: 10.1093/eurheartj/ehab551.Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806. DOI: 10.1093/eurheartj/ehab551.Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547-63. DOI: 10.1161/CIRCRESAHA.115.306249.Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547-63. DOI: 10.1161/CIRCRESAHA.115.306249.Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020;41(24):2288-99. DOI: 10.1093/eurheartj/ehaa172.Kaltoft M, Langsted A, Nordestgaard BG. Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J. 2020;41(24):2288-99. DOI: 10.1093/eurheartj/ehaa172.Nordestgaard BG, Varbo A.Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35. DOI: 10.1016/S0140-6736(14)61177-6.Nordestgaard BG, Varbo A.Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35. DOI: 10.1016/S0140-6736(14)61177-6.Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550-9. DOI: 10.1002/ana.25432.Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550-9. DOI: 10.1002/ana.25432.Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140(16):1308-17. DOI: 10.1161/CIRCULATIONAHA.119.041998.Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140(16):1308-17. DOI: 10.1161/CIRCULATIONAHA.119.041998.Hernandez P, Passi N, Modarressi T, et al. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep. 2021;23(11):72. DOI: 10.1007/s11883-021-00962-z.Hernandez P, Passi N, Modarressi T, et al. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep. 2021;23(11):72. DOI: 10.1007/s11883-021-00962-z.Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI: 10.1093/eurheartj/ehz455.Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI: 10.1093/eurheartj/ehz455.Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795-800. DOI: 10.1016/j.pan.2020.06.005.Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795-800. DOI: 10.1016/j.pan.2020.06.005.Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med. 2016;176(12):1834-42. DOI: 10.1001/jamainternmed.2016.6875.Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med. 2016;176(12):1834-42. DOI: 10.1001/jamainternmed.2016.6875.He WH, Zhu Y, Zhu Y, et al. Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes. Zhonghua Yi Xue Za Zhi. 2016;96(32):2569-72. (In Chinese) DOI: 10.3760/cma.j.issn.0376-2491.2016.32.011.He WH, Zhu Y, Zhu Y, et al. Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes. Zhonghua Yi Xue Za Zhi. 2016;96(32):2569-72. (In Chinese) DOI: 10.3760/cma.j.issn.0376-2491.2016.32.011.Pascual I, Sanahuja A, García N, et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients. Pancreatology. 2019;19(5):623-9. DOI: 10.1016/j.pan.2019.06.006.Pascual I, Sanahuja A, García N, et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients. Pancreatology. 2019;19(5):623-9. DOI: 10.1016/j.pan.2019.06.006.Zafrir B, Saliba W, Jubran A, et al. Severe Hypertriglyceridemia-Related Pancreatitis: Characteristics and Predictors of Recurrence. Pancreas. 2019;48(2):182-6. DOI: 10.1097/MPA.0000000000001235.Zafrir B, Saliba W, Jubran A, et al. Severe Hypertriglyceridemia-Related Pancreatitis: Characteristics and Predictors of Recurrence. Pancreas. 2019;48(2):182-6. DOI: 10.1097/MPA.0000000000001235.Wu BU, Batech M, Dong EY, et al. Influence of Ambulatory Triglyceride Levels on Risk of Recurrence in Patients with Hypertriglyceridemic Pancreatitis. Dig Dis Sci. 2019;64(3):890-7. DOI: 10.1007/s10620-018-5226-x.Wu BU, Batech M, Dong EY, et al. Influence of Ambulatory Triglyceride Levels on Risk of Recurrence in Patients with Hypertriglyceridemic Pancreatitis. Dig Dis Sci. 2019;64(3):890-7. DOI: 10.1007/s10620-018-5226-x.Мешков А. Н., Ершова А. И., Деев А. И. и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012-2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62-7. DOI: 10.15829/1728-8800-2017-4-62-67.Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the ESSE-RF study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (In Russ.) DOI: 10.15829/1728-8800-2017-4-62-67.Ежов М. В., Батлук Т. И., Токмин Д. С. и др. Распространенность дислипидемии до и на фоне пандемии COVID-19. Анализ большой лабораторной базы данных. Атеросклероз и Дислипидемии. 2023;(2):31-42. DOI: 10.34687/2219-8202.JAD.2023.02.0004.Ezhov MV, Batluk TI, Tokmin DS, et al. Prevalence of dyslipidemia before and during the COVID-19 pandemic. Analysis of a large laboratory database. Atherosclerosis and Dyslipidemia. 2023;(2):31-42 (In Russ.) DOI: 10.34687/2219-8202.JAD.2023.02.0004.Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:252. DOI: 10.3389/fendo.2020.00252.Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:252. DOI: 10.3389/fendo.2020.00252.Hegele RA, Ginsberg HN, Chapman MJ, et al; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655-66. DOI: 10.1016/S2213-8587(13)70191-8.Hegele RA, Ginsberg HN, Chapman MJ, et al; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655-66. DOI: 10.1016/S2213-8587(13)70191-8.Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455. DOI: 10.3389/fendo.2020.00455.Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455. DOI: 10.3389/fendo.2020.00455.Vasiluev PA, Ivanova ON, Semenova NA, et al. A Clinical Case of a Homozygous Deletion in the APOA5 Gene with Severe Hypertriglyceridemia. Genes (Basel). 2022;13(6):1062. DOI: 10.3390/genes13061062.Vasiluev PA, Ivanova ON, Semenova NA, et al. A Clinical Case of a Homozygous Deletion in the APOA5 Gene with Severe Hypertriglyceridemia. Genes (Basel). 2022;13(6):1062. DOI: 10.3390/genes13061062.Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI: 10.1111/joim.13016.Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI: 10.1111/joim.13016.Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648-61. DOI: 10.1038/nrcardio.2013.140.Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648-61. DOI: 10.1038/nrcardio.2013.140.Dussaillant C, Serrano V, Maiz A, et al. APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family. BMC Med Genet. 2012;13:106. DOI: 10.1186/1471-2350-13-106.Dussaillant C, Serrano V, Maiz A, et al. APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family. BMC Med Genet. 2012;13:106. DOI: 10.1186/1471-2350-13-106.Chait A, Eckel RH. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Ann Intern Med. 2019;170(9):626-34. DOI: 10.7326/M19-0203.Chait A, Eckel RH. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Ann Intern Med. 2019;170(9):626-34. DOI: 10.7326/M19-0203.Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. DOI: 10.15829/1560-4071-2023-5471.Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471 (In Russ.) DOI: 10.15829/1560-4071-2023-5471.Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials. Eur J Clin Invest. 2022;52(11):e13841. DOI: 10.1111/eci.13841.Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials. Eur J Clin Invest. 2022;52(11):e13841. DOI: 10.1111/eci.13841.Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401-12. DOI: 10.1093/eurheartj/ehab820.Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401-12. DOI: 10.1093/eurheartj/ehab820.Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729-37. DOI: 10.1038/s41591-023-02222-w.Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729-37. DOI: 10.1038/s41591-023-02222-w.Nishikido T, Ray KK. The power of lipid registries for cardiovascular disease prevention. Curr Opin Lipidol. 2021;32(6):342-8. DOI: 10.1097/MOL.0000000000000783.Nishikido T, Ray KK. The power of lipid registries for cardiovascular disease prevention. Curr Opin Lipidol. 2021;32(6):342-8. DOI: 10.1097/MOL.0000000000000783.Марцевич С. Ю., Кутишенко Н. П., Лукина Ю. В. и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная терапия и профилактика. 2021;20(2):2786. DOI: 10.15829/1728-8800-2021-2786.Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovascular Therapy and Prevention. 2021;20(2):2786 (In Russ.) DOI: 10.15829/1728-8800-2021-2786.EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-25. DOI: 10.1016/S0140-6736(21)01122-3.EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-25. DOI: 10.1016/S0140-6736(21)01122-3.Ariza MJ, Rioja J, Ibarretxe D, et al; Spanish Dyslipidemia Registry. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J Clin Lipidol. 2018;12(6):1482-1492.e3. DOI: 10.1016/j.jacl.2018.07.013.Ariza MJ, Rioja J, Ibarretxe D, et al; Spanish Dyslipidemia Registry. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J Clin Lipidol. 2018;12(6):1482-1492.e3. DOI: 10.1016/j.jacl.2018.07.013.Pang J, Li SCH, Chan DC, et al. Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):131-40. DOI: 10.1097/MED.0000000000000715.Pang J, Li SCH, Chan DC, et al. Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):131-40. DOI: 10.1097/MED.0000000000000715.Steinhagen-Thiessen E, Stroes E, Soran H, et al; GENIALL Investigators. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. Atherosclerosis. 2017;262:146-53. DOI: 10.1016/j.atherosclerosis.2016.08.023.Steinhagen-Thiessen E, Stroes E, Soran H, et al; GENIALL Investigators. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. Atherosclerosis. 2017;262:146-53. DOI: 10.1016/j.atherosclerosis.2016.08.023.Freedman S, de-Madaria E, Bruckert E, et al. Observed consensus on research priorities for the hypertriglyceridemia patient registry. Curr Med Res Opin. 2023;39(12):1629-35. DOI: 10.1080/03007995.2023.2235153.Freedman S, de-Madaria E, Bruckert E, et al. Observed consensus on research priorities for the hypertriglyceridemia patient registry. Curr Med Res Opin. 2023;39(12):1629-35. DOI: 10.1080/03007995.2023.2235153.Ежов М. В., Близнюк С. А., Тмоян Н. А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью, проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал. 2019;(5):7-13. DOI: 10.15829/1560-4071-2019-5-7-13.Ezhov MV, Bliznyuk SA, Tmoyan NA, et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian Journal of Cardiology. 2019;(5):7-13 (In Russ.) DOI: 10.15829/1560-4071-2019-5-7-13.Чубыкина У. В., Ежов М. В., Ершова А. И. и др. Сердечно-сосудистые осложнения и эффективность гиполипидемической терапии у пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска: три года наблюдения регистра РЕНЕССАНС. Кардиологический вестник. 2020;15(3):27-36. DOI: 10.36396/MS.2020.16.3.004.Chubykina UV, Ezhov MV, Ershova AI, et al. Cardiovascular events and effectiveness of hypolipidemic therapy in patients with familial hypercholesterolemia and patients of very high cardiovascular risk: 3-year follow-up of the RENAISSANCE Registry. Cardiology Bulletin. 2020;15(3):27-36 (In Russ.) DOI: 10.36396/MS.2020.16.3.004.Чубыкина У. В., Ежов М. В., Рожкова Т. А. и др. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС. Атеросклероз и Дислипидемии. 2023;(1):5-18 DOI: 10.34687/2219-8202.JAD.2023.01.0001.Chubykina UV, Ezhov MV, Rozhkova TA, et al. A five-year follow-up period in homo- and heterozygous familial hypercholesterolemia patients of the RENAISSANCE registry. Atherosclerosis and Dyslipidemia. 2023;(1):5-18 (In Russ.) DOI: 10.34687/2219-8202.JAD.2023.01.0001.Чубыкина У. В., Ежов М. В., Рожкова Т. А. и др. Комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией: 5 лет наблюдения регистра РЕНЕССАНС. Кардиологический вестник. 2023;18(3):35-48. DOI: 10.17116/Cardiobulletin20231803135.Chubykina UV, Ezhov MV, Rozhkova TA, et al. Compliance of patients with heterozygous familial hypercholesterolemia: 5-year follow-up of the renaissance registry. Russian Cardiology Bulletin. 2023;18(3):35-48. (In Russ.) DOI: 10.17116/Cardiobulletin20231803135.

The authors declare that there are no conflicts of interest present.